Table 5.
Outcome | Model | Features | Class | N. class | Precision | Recall | F1 | Acc. | AUC |
---|---|---|---|---|---|---|---|---|---|
TTF3
Class 0 (TTF<3m) 213 patients Class 1 (TTF3≥6m) 267 patients |
CB | 27 | 0 | 23 | 0.79 | 0.83 | 0.81 | 0.81 | 0.81 |
1 | 25 | 0.83 | 0.80 | 0.82 | |||||
LR | 9 | 0 | 23 | 0.76 | 0.70 | 0.73 | 0.75 | 0.79 | |
1 | 25 | 0.74 | 0.80 | 0.78 | |||||
NN | 10 | 0 | 23 | 0.74 | 0.74 | 0.74 | 0.75 | 0.78 | |
1 | 25 | 0.76 | 0.76 | 0.76 | |||||
RF | 5 | 0 | 23 | 0.57 | 0.57 | 0.57 | 0.58 | 0.65 | |
1 | 25 | 0.60 | 0.60 | 0.60 | |||||
SVM | 11 | 0 | 23 | 0.53 | 0.78 | 0.63 | 0.56 | 0.51 | |
1 | 25 | 0.64 | 0.36 | 0.46 |
ACC, testing accuracy; AUC, area under the curve; TTF3, 3-months’ time to treatment failure; N. class, number of patients in both classes for a test set. Bold is the best performing model for this outcome.